FINANCINGS
Abeona Therapeutics Inc. closed an upsized $15.5 million direct placement of registered common stock.
Amag Pharmaceuticals Inc. closed a public offering of common stock, for gross proceeds of about $230.9 million.
Celgene Corp. priced five series of senior unsecured notes, maturing between 2018 and 2045, with a total principal amount of $8 billion.
Egalet Corp. completed its public offering of about 7.6 million shares at $11.25 each, for gross proceeds of about $86.3 million.
Genocea Biosciences Inc. closed a public offering of 3.85 million common shares at $13 each, raising approximately $50 million.
Global Blood Therapeutics Inc. set terms for its proposed IPO, planning to sell 6 million shares priced between $16 and $18.
Intec Pharma Ltd. priced its U.S. IPO of approximately 5 million ordinary shares at $6 each, expecting to raise about $30 million.
Metacrine Inc. has raised $36 million in a series A financing round.
Nantkwest Inc. closed its IPO for net proceeds of about $222.5 million.
Ocera Therapeutics Inc. said it secured a $20 million debt facility from Oxford Finance LLC and Silicon Valley Bank.
Soligenix Inc. entered a $10 million equity purchase agreement with accredited institutional investors.
Zogenix Inc. closed its public offering for gross proceeds total about $98.3 million.
Zynerba Pharmaceuticals Inc. priced its IPO of 3 million shares at $14 apiece for gross proceeds of $42 million.
DEALS
Astrazeneca plc has signed a biosimilar joint venture with Fujifilm Kyowa Kirin Biologics Co. Ltd. targeting blockbuster cancer drugs.
Cloud Pharmaceuticals Inc. has partnered with Genomeon LLC designed to enable Cloud to offer companion biomarkers as part of its drug development process.
Dr. Reddy's Laboratories Ltd. entered a collaboration with Amgen Inc. to market and distribute three of Amgen's medicines in India.
Ironwood Pharmaceuticals Inc. inked a deal with Allergan plc for the U.S. co-promotion of Viberzi, Allergan's treatment for adults with irritable bowel syndrome with diarrhea.
Pfizer Inc. said the European Commission has approved the pending acquisition of Hospira Inc.
Pharmaxis Ltd. and Synairgen plc will co-develop a selective inhibitor to the lysyl oxidase type 2 enzyme to treat the fatal lung disease idiopathic pulmonary fibrosis.
Shire plc is bolstering its ophthalmology offerings with the acquisition of Foresight Biotherapeutics Inc. for $300 million in cash.
Shire plc has made an unsolicited $33.9 billion all-stock offer for Baxalta Inc.
. . . AND MORE
Ampliphi Biosciences Corp. is conducting a 1-for-50 reverse split of the company's common stock.
Bayer AG received FDA approval for Finacea (azelaic acid) Foam 15 percent for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Emergent Biosolutions Inc. plans to pursue a tax-free spinoff of the company's biosciences business into a separate, standalone publicly traded company.
Marina Biotech Inc. received FDA fast track designation for CEQ508, an RNAi therapeutic for the treatment of familial adenomatous polyposis.